Dr. Heymach on the Significance of Nivolumab for Lung Cancer

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.

The long-term follow-up for nivolumab is important for the field, states Heymach. Overall, patients in the CheckMate-026 trial saw an improvement in survival of a few months.

The long-term data informs researchers that there are some patients that are still benefitting from the treatment years later, explains Heymach.